- participant has a clinically significant acute illness (this does not include minor illnesses such as diarrhea or mild upper respiratory tract infection) or temperature ≥38.0ºc within 24 hours prior to the planned dose of study vaccine. - participant has a known or suspected allergy or history of anaphylaxis or other serious adverse reactions to comirnaty excipients. - subjects with any contraindication to the administration of comirnaty, included pregnancy. - subjects with prior documented covid19 since vaxzevria vaccination. - subjects have symptoms or signs compatible with covid19. - subjects participating in a clinical trial in the last three months. - any condition or situation precluding or interfering the compliance with the protocol.

- participant has a clinically significant acute illness (this does not include minor illnesses such as diarrhea or mild upper respiratory tract infection) or temperature ≥38.0ºc within 24 hours prior to the planned dose of study vaccine. - participant has a known or suspected allergy or history of anaphylaxis or other serious adverse reactions to comirnaty excipients. - subjects with any contraindication to the administration of comirnaty, included pregnancy. - subjects with prior documented covid19 since vaxzevria vaccination. - subjects have symptoms or signs compatible with covid19. - subjects participating in a clinical trial in the last three months. - any condition or situation precluding or interfering the compliance with the protocol.